Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposing Mefloquine for Pancreatic Cancer Treatment
NCT07875907Phase 1Not yet recruiting
- Sponsor
- University of Florida
- Start
- Nov 2026
- Primary completion
- Jan 2029
01
Overview
Phase 1, open-label trial of mefloquine in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by University of Florida. Primary endpoint: Recommended Phase 2 Dose at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mefloquine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07875907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875907.